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Patients with multiple myeloma (MM) will relapse
despite treatment with conventional chemotherapy or
high-dose chemotherapy with autologous stem cell trans-
plantation (ASCT) (1). Newer agents in MM such as
thalidomide, bortezomib, and lenalidomide have
improved survival rates of patients with this disease.
Combinations of these new agents have shown response
rates superior to standard chemotherapy and rivalling
ASCT (2–11). Nevertheless, the best treatment regimen,
combinations or sequence of therapy for patients with
this incurable disease in the second-line setting have yet
to be standardized.
Lenalidomide is an oral immunomodulatory drug with
demonstrated efﬁcacy and tolerability in MM (2–5). It
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This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple
myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse. Multi-
variate analysis showed that fewer prior therapies, along with b2-microglobulin (£2.5 mg ⁄L), predicted a
better time to progression (TTP; study end-point) with lenalidomide plus dexamethasone treatment.
Patients with one prior therapy showed a significant improvement in benefit after first relapse compared
with those who received two or more therapies. Patients with one prior therapy had significantly pro-
longed median TTP (17.1 vs. 10.6 months; P = 0.026) and progression-free survival (14.1 vs. 9.5 months,
P = 0.047) compared with patients treated in later lines. Overall response rates were higher (66.9% vs.
56.8%, P = 0.06), and the complete response plus very good partial response rate was significantly higher
in first relapse (39.8% vs. 27.7%, P = 0.025). Importantly, overall survival was significantly prolonged for
patients treated with lenalidomide plus dexamethasone with one prior therapy, compared with patients
treated later in salvage (median of 42.0 vs. 35.8 months, P = 0.041), with no differences in toxicity, dose
reductions, or discontinuations despite longer treatment. Therefore, lenalidomide plus dexamethasone is
both effective and tolerable for second-line MM therapy and the data suggest that the greatest benefit
occurs with earlier use.
Key words lenalidomide; multiple myeloma; relapse; time to progression; survival
Correspondence Dr Edward A. Stadtmauer, Abramson Cancer Center, University of Pennsylvania School of Medicine, 16 Penn
Tower, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Tel: + 1 215 662 7910; Fax: +1 215 662 4064; e-mail: edward.
stadtmauer@uphs.upenn.edu
Accepted for publication 9 March 2009 doi:10.1111/j.1600-0609.2009.01257.x
Re-use of this article is permitted in accordance with the
Creative Commons Deed, Attribution 2.5, which does
not permit commercial exploitation.
ORIGINAL ARTICLE
European Journal of Haematology ISSN 0902-4441
426
ª 2009 The Authors
Journal compilation 82 (426–432) ª 2009 Blackwell Munksgaard
has been approved for clinical use in the USA, Europe,
and Canada for previously treated MM based on the
results from two phase III trials – MM-009 and
MM-010. These trials assessed patients in relapsed or
refractory disease with a median of two and three prior
therapies, respectively (2, 3).
The aim of this subset analysis of the MM-009 and
MM-010 studies was to evaluate the beneﬁt of lenalido-
mide plus dexamethasone after only one prior therapy
and compare outcomes for patients treated in later sal-
vage therapy. This is the ﬁrst such analysis, and these
data will provide a valuable insight when considering the
overall treatment plan and therapy sequence for patients.
Methods
Study design
Patients treated with lenalidomide plus dexamethasone
enrolled in the two large, randomized, multicentre clinical
trials of lenalidomide plus dexamethasone vs. dexametha-
sone alone [MM-009 (2) and MM-010 (3)] were included
in this preplanned analysis. In the MM-009 and MM-010
studies, patients with MM who had received at least one
prior treatment, and were not resistant to dexamethasone,
were randomized to receive either oral lenalidomide
(25 mg daily for 21 d of every 28-d cycle) plus dexametha-
sone (40 mg on day 1–4, 9–12, and 17–20 every 28 d
for 4 months, then 40 mg on day 1–4 every cycle
thereafter until disease progression or treatment
intolerance), or dexamethasone (same dose and schedule
as above) plus placebo. Patients were stratiﬁed at random-
ization by investigator-reported baseline b2-microglobulin
(£ 2.5 mg ⁄L vs. >2.5 mg ⁄L), prior therapies (whether or
not the patient had undergone prior treatment with high-
dose chemotherapy, and stem cell transplantation) and
number of prior therapies (1 vs. >1).
For this analysis, determination of number of prior
lines of antimyeloma therapy was retrospectively assessed
in order to derive a uniform deﬁnition of line of therapy:
1. Induction chemotherapy for peripheral-blood stem cell
harvest followed by planned mobilization and subse-
quent high-dose chemotherapy with ASCT was consid-
ered one therapy regardless of the induction regimen.
2. If the ﬁrst treatment was followed by maintenance
with interferon or steroids, then it was still consid-
ered as one line of therapy. Maintenance therapy
was not considered a separate line of therapy.
3. Two ASCTs within 6 months of each other was con-
sidered as one line unless different agents were used
in the high-dose therapy-conditioning regimens.
4. If the same regimen was repeated after a 6-month
interval, they were considered to be two separate
therapeutic lines.
5. If cyclophosphamide was used for reasons other than
planned stem cell mobilization, its use was considered
to be a separate line of therapy.
6. If dexamethasone was used once, it did not count as
a line of therapy.
7. If a regimen was stopped for more than 2 months, its
reinitiation was counted as another line of therapy.
The international uniform response criteria for MM
were used to evaluate response (12) and the European
Group for Blood and Marrow Transplant response
criteria for MM (13) were used to evaluate time to progres-
sion (TTP) and progression-free survival (PFS) per
protocol. TTP was measured from randomization to the
date of the ﬁrst assessment showing disease progression.
Patients who died or discontinued the study without evi-
dence of disease progression were censored at the last eval-
uation for assessment of TTP. PFS was measured from
randomization to the date of the ﬁrst assessment showing
disease progression, or death during treatment. Patients
who were alive and discontinued the study without evi-
dence of disease progression were censored at the last eval-
uation for assessment of PFS. Overall survival (OS) was
calculated as the time from randomization until death
from any cause, or censored at the last follow-up visit.
Overall response rate (ORR), TTP, PFS, and OS were all
evaluated as measures of clinical beneﬁt. Toxic effects were
graded according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC), version 2.
Statistical analysis
The MM-009 and MM-010 trials were initiated on 27
February 2003, and 22 September 2003, respectively.
Unblinding occurred in June and August 2005, respec-
tively, due to demonstrated superiority of lenalidomide
plus dexamethasone over dexamethasone alone at the
interim analysis and upon recommendation of the
studies’ independent data-monitoring committee. Data
on ORR, TTP, PFS, and OS were assessed up to these
dates, with a median follow-up duration of
17.6 months (range: 11.0–25.6) for active patients.
Follow-up data on OS have been updated and were
obtained up to 11 December 2008, and the median fol-
low-up duration for surviving patients was 51 months
(range: 0.6–66.5).
Analyses of patients treated with lenalidomide plus
dexamethasone (n = 353) were conducted using sas ver-
sion 9.1 [Lenalidomide (Revlimid), Celgene Corpora-
tion, Summit, NJ, USA]. The Cox proportional hazards
model was ﬁrst performed as an exploratory analysis to
determine which demographic and prognostic variables
most affected the primary efﬁcacy end-point, TTP. Only
those variables that differed from a preliminary analysis
at the 0.20 level were included in the ﬁnal multivariate
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model. A forward-selection stepwise procedure was used
to identify the subset of relevant factors.
The ﬁnal model showed that the number of prior
therapies was one of the only two signiﬁcant predictors
for TTP, after controlling for other baseline variables.
Therefore, further analysis was conducted using a
univariate model to examine the efﬁcacy outcome of
the patient subgroups in the combination arm, with
one prior therapy vs. those with at least two prior
therapies.
Kaplan–Meier methods were used to estimate time-
to-event variables with censoring, including TTP, PFS,
OS, and response duration. Two-sided log rank tests
were used to compare survivorship functions between
treatment groups for these time-to-event end-points.
Fisher’s exact tests were used to compare response
rates. All of the analyses were performed without
prespeciﬁed power calculation or adjustment for




Variables assessed in the preliminary multivariate Cox
regression model included the following baseline charac-
teristics: gender, age, race, percentage of plasma cells in
the bone marrow, time since diagnosis, baseline Eastern
Cooperative Oncology Group performance status, base-
line disease stage, presence of worsening lytic bone
lesions at baseline, b2-microglobulin, prior thalidomide,
prior bortezomib, prior radiation therapy, duration of
MM, whether there was presence of baseline bone
lesions, and the number of prior antimyeloma therapies,
including stem cell transplantation. Only those variables
that differed from the preliminary analysis at the 0.20
level were included in the ﬁnal multivariate model. The
ﬁnal model showed that number of prior therapies was
one of the only two signiﬁcant baseline prognostic fac-
tors that predicted TTP for patients treated with lenalid-
omide plus dexamethasone (Table 1). In other words, the
fewer prior therapies a patient had, the less likely it is
that the disease will progress and the longer the TTP will
be. Use of prior thalidomide or bortezomib did not
impact the TTP outcome (i.e. these two variables were
not included in the ﬁnal model).
Given that the number of prior therapies was a signiﬁ-
cant predictor of TTP, further analysis was performed to
compare the subgroups of lenalidomide plus dexametha-
sone-treated patients (i.e. those who had received one
prior therapy vs. those who had received two or more
therapies) in terms of efﬁcacy outcome, as well as the
baseline characteristics.
Baseline characteristics
Of 353 patients who received lenalidomide plus dexa-
methasone, 133 had received one prior therapy before
this combination therapy, and 220 had received two or
more prior therapies. Signiﬁcant baseline differences in
those patients who had received one prior therapy vs.
those with two or more prior therapies include: prior
ASCT (66.9% vs. 53.2%; P = 0.014); prior treatment
with thalidomide (9.8% vs. 51.8%; P < 0.001); and
prior treatment with bortezomib (1.5% vs. 11.4%;
P < 0.001) (Table 2). The average length of time from
diagnosis was also signiﬁcantly different between patients
with one prior therapy and those who had received two
or more prior therapies (2.2 yr vs. 4.1 yr; P < 0.001).
Treatment
Patients with one prior therapy had a median treatment
duration of 12.5 months (range: 0.3–24.1) which was
higher than that for patients with two or more prior
Table 1 Multivariate analysis (n = 353)
Variable HR 95% CI P-value
b2-microglobulin
(>2.5 mg ⁄ L vs. £2.5 mg ⁄ L)
1.622 1.280–2.056 <0.0001
Number of prior antimyeloma
therapies
1.181 1.056–1.321 0.0032
Duration of multiple myeloma (yr) 0.964 0.928–1.002 0.0614
Age (yr) 0.991 0.981–1.002 0.0958
CI, confidence interval; HR, hazard ratio.
Table 2 Baseline characteristics and treatment history of patients







(n = 220) P-value
Median age, yr 62.1 63.1 0.34
Male sex, n (%) 82 (61.7) 128 (58.2) 0.58
Baseline b2-microglobulin
£2.5 mg ⁄ L, n (%)
47 (35.3) 56 (25.5) 0.054
Baseline b2-microglobulin
>2.5 mg ⁄ L, n (%)
86 (64.7) 164 (74.5) 0.054
ECOG score 0–1, n (%) 119 (89.5) 188 (85.5) 0.77
Median time from diagnosis,
yr (range)
2.2 (0.4–9.7) 4.1 (0.5–15.7) <0.001
Prior ASCT, n (%) 89 (66.9) 117 (53.2) 0.014
Prior treatment with
thalidomide, n (%)
13 (9.8) 114 (51.8) <0.001
Prior treatment with
bortezomib, n (%)
2 (1.5) 25 (11.4) <0.001
ASCT, autologous stem cell transplantation; ECOG, Eastern Coopera-
tive Oncology Group.
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therapies (9.2 months, range: 0.03–24.8; P < 0.001)
(Table 3).
The proportion of patients who had a dose reduction,
with or without interruption of lenalidomide treatment,
was similar among those who had undergone either one
or at least two prior therapies (33.1% vs. 38.0%;
P = 0.36). There was also no signiﬁcant difference in
discontinuation rates due to toxicity between these
patients (14.3% vs. 14.5%; P = 0.54).
Response
Patients who had received one prior therapy had a trend
towards a higher ORR than those receiving at least two
prior therapies (66.9% vs. 56.8%; P = 0.06) (Table 3).
However, more patients who had one prior therapy
achieved a complete response or a very good partial
response (CR + VGPR; 39.8%) compared with those
who had two or more prior therapies (27.7%; P = 0.025).
With a median follow-up of 15.5 months for responders,
the median duration of response had not been reached in
the cohort who had received only one prior therapy,
whereas those patients with two or more prior therapies
had a median response duration of 13.0 months
(P = 0.21). Fewer responders receiving one prior therapy
(38.2%) had relapsed compared with those receiving two
or more therapies (45.6%) at the time of study unblinding.
TTP was signiﬁcantly longer for patients who had
received one prior therapy compared with those who had
at least two prior therapies (17.1 months vs. 10.6 months;
hazard ratio (HR) 0.68; 95% conﬁdence interval (CI)
0.48–0.97; P = 0.026) (Fig. 1). PFS was also signiﬁcantly
longer in patients who had received one prior therapy
compared with those who had received two or more prior
lines of therapy (median of 14.1 months vs. 9.5 months;
HR 0.71; 95% CI 0.2–0.99; P = 0.047) (Fig. 2).
OS from study enrollment was signiﬁcantly longer in
patients who had received one prior therapy than in
those who had received at least two prior lines of ther-
apy at the time of unblinding (median not reached vs.
30.8 months, HR 0.59; 95% CI 0.36–0.95; P = 0.028).
Importantly, this signiﬁcant survival advantage was sus-
tained with the extended follow-up based on data as of
December 2008 (median OS of 42.0 vs. 35.8 months,
P = 0.041) (Fig. 3).








(n = 220) P-value
Response rates, n (%)
Overall response 89 (66.9) 125 (56.8) 0.060
CR 27 (20.3) 26 (11.8) 0.028
VGPR 26 (19.5) 35 (15.9)
CR + VGPR 53 (39.8) 61 (27.7) 0.025
Partial response 36 (27.1) 64 (29.1)
Stable disease 30 (22.6) 77 (35.0)
Progressive disease 6 (4.5) 2 (0.9)
Response not evaluable 8 (6.0) 16 (7.3)
Median duration of treatment,
months (range)
12.5 (0.3–24.1) 9.2 (0.03–24.8) <0.001
Median duration of response,
months (range)
NR (11.4–NR) 13.0 (8.4–NR) 0.21
Patients who relapsed, % 34.5 44.4 0.16
Patients who had a dose
reduction1, %
33.1 38.0 0.36
Patients who discontinued due
to toxicity, %
14.3 14.5 0.54
1With or without interruption in lenalidomide treatment.
NR, not reached; CR, complete response; VGPR, very good partial response.





100 1 prior therapy (len/dex),
median 17.1 months
≥2 prior therapies (len/dex),
median 10.6 months







Figure 1 Kaplan–Meier estimates of the time to progression of
patients who received lenalidomide plus dexamethasone (len ⁄ dex) by
number of prior therapies (P = 0.026), using data up to unblinding.
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Safety
NCI-CTC grade 3 and 4 neutropenia was the most com-
mon adverse event associated with lenalidomide plus dexa-
methasone treatment in patients with one prior therapy,
and in those with at least two prior therapies (41.4% vs.
31.8%) (Table 4). There was no difference in the incidence
of febrile neutropenia between patients with one prior
therapy and those with two or more prior therapies (1.6%
vs. 2.6%; P = 0.72). Thrombotic events, including deep-
vein thrombosis and pulmonary embolism, were the most
common grade 3 and 4 non-hematologic toxicities, occur-
ring in 10.5% of patients with one prior therapy vs. 12.3%
of those with at least two prior therapies (P = 0.63). No
grade 3 and 4 peripheral neuropathy was observed in
patients treated with lenalidomide plus dexamethasone
with one prior therapy, whereas it was reported in 2.3% of
the patients with two or more prior therapies.
Discussion
The results of this analysis of pooled data from the two
phase III studies MM-009 and MM-010 assessing lena-
lidomide plus dexamethasone showed that patients with
fewer prior treatments will beneﬁt more from this active
combination. The number of lines of treatment had a
greater impact than the type of prior therapy (e.g. prior
thalidomide or bortezomib treatment). The ORR after
receiving lenalidomide plus dexamethasone was higher in
patients receiving lenalidomide plus dexamethasone after
only one prior therapy compared with those with two or
more prior therapies, although the difference was not
statistically signiﬁcant. These overall results are consis-
tent with the results previously reported by Wang et al.
for the subset of patients who receive prior thalidomide
(14). The quality of response was signiﬁcantly better in
patients receiving lenalidomide plus dexamethasone after
only one prior therapy, as shown by the statistically
higher CR and VGPR rates in these patients. In addi-
tion, duration of response was longer in patients with
one prior therapy compared with those with two or more
prior therapies. The median TTP reached in this study
for patients treated in the second-line setting was
17.1 months. This signiﬁcant beneﬁt was diminished if le-
nalidomide plus dexamethasone treatment was given
later in treatment. The median OS at 42 months was also
signiﬁcantly longer for those with only one prior therapy
than for those with two or more prior therapies and is
among the longest reported in the literature to date for
these patients (2–11).
The incidence of NCI-CTC grade 3 and 4 adverse events
was similar for patients who had had either one or at least
two prior therapies, with neutropenia occurring most fre-
quently. The incidence of thrombotic events was compara-
ble between the two groups. Overall, treatment with
lenalidomide plus dexamethasone was well tolerated, with
a signiﬁcantly longer treatment duration for ﬁrst relapse
compared to later lines of therapy. This longer treatment
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Figure 2 Kaplan–Meier estimates of progression-free survival in the
lenalidomide plus dexamethasone (len ⁄ dex) group by number of prior
therapies (P = 0.047), using data up to unblinding.
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Figure 3 Kaplan–Meier estimates of overall survival in the lenalido-
mide plus dexamethasone (len ⁄ dex) group by number of prior thera-
pies (P = 0.041), using updated data as of December 2008.
Table 4 Incidence of National Cancer Institute Common Toxicity









Hematologic toxicities, n (%)
Anemia 13 (9.8) 25 (11.4)
Thrombocytopenia 12 (9.0) 34 (15.5)
Neutropenia 55 (41.4) 70 (31.8)
Infection 24 (18.0) 29 (13.2)
Febrile neutropenia 2 (1.6) 6 (2.6)
Non-hematologic toxicities, n (%)
Deep-vein thrombosis ⁄ pulmonary
embolism
14 (10.5) 27 (12.3)
Peripheral neuropathy 0 (0.0) 5 (2.3)
Fatigue 10 (7.5) 13 (5.9)
GI (nausea, vomiting, constipation) 8 (6.0) 7 (3.2)
GI, gastrointestinal.
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duration in the second line did not generally increase tox-
icity, rate of dose reduction, or treatment discontinuation
compared to later lines of therapy with shorter treatment
duration. For those patients with one or two or more prior
therapies, the incidence of treatment-emergent peripheral
neuropathy was low. It is interesting to note that despite
being a more heavily pretreated group, those with two or
more prior therapies generally did not experience more
treatment-emergent adverse events.
The patients in this study with one prior therapy were
not only less heavily pretreated, they were also fewer
years from diagnosis than those with two or more prior
therapies. This could account for potential differences in
the biology of the disease and could likely explain, in
part, the better outcomes observed for patients in ﬁrst
relapse. However, b2-microglobulin, a typical strong pre-
dictor of patient outcomes and indicator of advanced
disease, was not statistically different in these two patient
subsets. It must also be noted that these results were
achieved at a time when novel agents were rarely used
upfront, and results might be different in patients who
received novel agents as ﬁrst-line treatment.
Results of this overall analysis of ﬁrst relapse from the
MM-009 ⁄MM-010 phase III studies conﬁrmed those previ-
ously reported by Wang et al. speciﬁcally for lenalidomide
plus dexamethasone after thalidomide treatment (14).
Wang reported that lenalidomide plus dexamethasone
received as second-line therapy immediately after thalido-
mide treatment, resulted in a higher ORR and longer med-
ian TTP than when used later in the treatment, after other
additional therapies. This further supports the signiﬁcant
role of lenalidomide plus dexamethasone as second-line
treatment, regardless of prior exposure to thalidomide.
In conclusion, lenalidomide plus dexamethasone treat-
ment resulted in signiﬁcantly prolonged TTP, PFS, and
OS, as well as better quality of response, when used at
ﬁrst relapse compared with its use later as salvage ther-
apy. Lenalidomide plus dexamethasone should be consid-
ered as a second-line therapy for patients with MM.
Trials using lenalidomide plus dexamethasone are also
underway to conﬁrm beneﬁts earlier in MM treatment as
part of ﬁrst-line therapy.
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